SCHEMBL2948476

SCHEMBL2948476

COc1ccc2nc(Cl)nc(Cl)c2c1OC

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.53
PDE3A Q14432 2/20 0.53
AMY1A P0DUB6 2/20 0.40
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPK1 P28482 1/20 0.40
CYP1A1 P04798 2/20 0.38
CYP1B1 Q16678 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP19A1 P11511 1/20 0.37
HTT P42858 1/20 0.36
KCNA5 P22460 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NQO2 P16083 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28038544 0.85 PDE3B (0.51) PDE3BPDE3AAMY1AALDH1A1KDM4E
SCHEMBL27248807 0.84 PDE3B (0.40) PDE3BPDE3AAMY1AALDH1A1KDM4E
SCHEMBL27248563 0.84 ALDH1A1 (0.37) PDE3BPDE3AALDH1A1KDM4EHSD17B10
SCHEMBL4738100 0.83 PDE3A (0.50) PDE3BPDE3AAMY1AALDH1A1HPGD
SCHEMBL27248956 0.83 PDE3B (0.42) PDE3BPDE3AALDH1A1KDM4EHPGD
SCHEMBL11209986 0.79 SMN1; SMN2 (0.45) PDE3BPDE3AALDH1A1KDM4EHSD17B10
SCHEMBL30402363 0.77 ALDH1A1 (0.53) AMY1AALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL1478324 0.77 ALDH1A1 (0.53) AMY1AALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL8807809 0.76 EGFR (0.48) PDE3BPDE3AAMY1AALDH1A1KDM4E
SCHEMBL16689300 0.75 SMN1; SMN2 (0.44) AMY1AALDH1A1KDM4ESMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0227450-A2 Substituted 5,6-Dialkoxyquinazoline Derivatives ORTHO PHARMACEUTICAL CORPORATION (US) 1987-07-01 EP claimed
US-4672116-A CARDIOTONIC AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1987-06-09 US claimed
US-20240408092-A1 PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES UNIV CASE WESTERN RESERVE (US) 2024-12-12 US disclosed
US-11944624-B2 Peptide and small molecule agonists of EphA and their uses CASE WESTERN RESERVE UNIVERSITY (US) 2024-04-02 US disclosed
US-20200222405-A1 PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES CASE WESTERN RESERVE UNIVERSITY 2020-07-16 US disclosed
EP-3648766-A1 PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES Case Western Reserve University (US) 2020-05-13 EP disclosed
WO-2019010180-A1 PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES CASE WESTERN RESERVE UNIVERSITY (US) 2019-01-10 WO disclosed
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS AMBIT BIOSCIENCES CORPORATION 2010-07-08 US disclosed
US-7750160-B2 Isoxazolyl urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION (US) 2010-07-06 US disclosed
EP-1684762-A4 UREA DERIVATIVES AS KINASE MODULATORS AMBIT BIOSCIENCES CORP (US) 2009-06-17 EP disclosed
EP-1684762-A2 UREA DERIVATIVES AS KINASE MODULATORS Ambit Biosciences Corporation (US) 2006-08-02 EP disclosed
US-20050267182-A1 Urea derivatives as FLT-3 modulators AMBIT BIOSCIENCES CORPORATION 2005-12-01 US disclosed
US-20050197371-A1 Urea derivatives as PDGFR modulators AMBIT BIOSCIENCES CORPORATION 2005-09-08 US disclosed
US-20050192314-A1 Urea derivatives as C-kit modulators AMBIT BIOSCIENCES CORPORATION 2005-09-01 US disclosed
US-20050165031-A1 Urea derivatives as ABL modulators AMBIT BIOSCIENCES CORPORATION 2005-07-28 US disclosed
US-20050165024-A1 Urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION 2005-07-28 US disclosed
WO-2005048948-A2 UREA DERIVATIVES AS KINASE MODULATORS AMBIT BIOSCIENCES CORPORATION (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200222405-A1 PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES EPHA1, EPHA7, EPHA3 PDE3B 1497/4885PDE3A 1665/4885AMY1A 3793/4885
US-20050165024-A1 Urea derivatives as kinase modulators ULK2, ULK1, ULK3 PDE3B 775/4885PDE3A 788/4885AMY1A 3856/4885
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS ABL1, ABL2, BCR PDE3B 1141/4885PDE3A 956/4885AMY1A 4856/4885
US-20050192314-A1 Urea derivatives as C-kit modulators KIT, PRKCH, PRKCE PDE3B 336/4885PDE3A 385/4885AMY1A 4150/4885
US-20050267182-A1 Urea derivatives as FLT-3 modulators FLT4, FLT1, FLT3 PDE3B 51/4885PDE3A 41/4885AMY1A 4834/4885
US-11944624-B2 Peptide and small molecule agonists of EphA and their uses EPHA1, EPHA7, EPHA3 PDE3B 1497/4885PDE3A 1665/4885AMY1A 3793/4885
US-20240408092-A1 PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES EPHA1, EPHA7, EPHA3 PDE3B 1497/4885PDE3A 1665/4885AMY1A 3793/4885
US-20050197371-A1 Urea derivatives as PDGFR modulators PDGFRA, PDGFRB, PDGFA PDE3B 132/4885PDE3A 148/4885AMY1A 4772/4885
US-20050165031-A1 Urea derivatives as ABL modulators ABL1, ABL2, BCR PDE3B 1141/4885PDE3A 956/4885AMY1A 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.